Back to Search
Start Over
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
- Source :
- Cancer immunology, immunotherapy : CII. 69(8)
- Publication Year :
- 2019
-
Abstract
- Tumor-infiltrating lymphocytes (TILs) and their subsets contribute to breast cancer prognosis. We investigated the prognostic impact of CD3+, CD8+ and FOXP3+ TILs in patients with early intermediate/high-risk breast cancer treated with adjuvant anthracycline-based chemotherapy within two randomized trials conducted by our Group. We examined 1011 patients (median follow-up 130.9 months) and their tumors for total, stromal (s) and intratumoral (i) CD3, CD8 and FOXP3 lymphocyte density (counts/mm2) on tissue-microarray cores by immunohistochemistry. Morphological sTIL density on whole H&E-stained sections was also evaluated. The majority of TILs were CD3+. Total CD3 and CD8, sCD3 and sCD8, iCD3 and iCD8, sFOXP3 and iFOXP3 were strongly correlated (Spearman’s rho values > 0.6). High individual lymphocytic subsets and sTIL density were strongly associated with high tumor grade, higher proliferation and HER2-positive and triple-negative tumors (all p values
- Subjects :
- Adult
Cancer Research
Stromal cell
Anthracycline
CD3 Complex
Lymphocyte
medicine.medical_treatment
CD8 Antigens
Immunology
Breast Neoplasms
Lower risk
03 medical and health sciences
Young Adult
0302 clinical medicine
Breast cancer
Lymphocytes, Tumor-Infiltrating
Biomarkers, Tumor
Immunology and Allergy
Medicine
Humans
Stromal tumor
Aged
Chemotherapy
business.industry
Forkhead Transcription Factors
Middle Aged
medicine.disease
Prognosis
Lymphocyte Subsets
medicine.anatomical_structure
Oncology
Chemotherapy, Adjuvant
Cancer research
Immunohistochemistry
Female
Radiotherapy, Adjuvant
Stromal Cells
business
030215 immunology
Follow-Up Studies
Subjects
Details
- ISSN :
- 14320851
- Volume :
- 69
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Cancer immunology, immunotherapy : CII
- Accession number :
- edsair.doi.dedup.....8bb75772790846b416431e24f5f5a0bb